HLS Therapeutics (HLS) Q3 2025 earnings summary

Executive summary

• Adjusted EBITDA increased 19% in Q3 and 25% year-to-date, reflecting operational improvements and cost discipline, with 87% growth since Q3 2023 when excluding royalties.

• Cash from operations rose 67% in Q3 and 121% year-to-date, driven by improved profitability and lower operating expenses.

• Product sales in Canada grew 2% year-to-date in local currency, but Q3 revenues declined 4% due to headwinds, inventory effects, and FX impacts.

• Vascepa/Pasipa prescriptions grew 24% year-to-date, with Q3 being the most profitable quarter since launch; consistent prescribers up 29% from Q3 last year.

• U.S. Clozaril business outperformed expectations, showing stability and 1% year-to-date growth, while Canadian Clozaril patient numbers declined less than 1% year-over-year but rose 1% since end of 2023, with regional growth offset by attrition and competition.

Financial highlights

• Q3 revenue was $13.5M, down from $14.1M last year; year-to-date revenue was $40.3M, down from $41.1M.

• Adjusted EBITDA grew 19% in Q3 and 25% year-to-date; trailing twelve-month adjusted EBITDA up 87% since Q3 2023.

• Q3 operating expenses were down 22% year-over-year; year-to-date, down 20%, reflecting operational efficiency.

• Cash from operations in Q3 was $2.5M, up 67% year-over-year; year-to-date, $10.6M, up 121%.

• Net debt at quarter end was $43.5M, down from $50M at December 31, 2024; bank debt reduced by 41% since Q3 2023.

Outlook and guidance

• Adjusted EBITDA for the full year expected to grow 17%-23%, reaching $19.5-$20.5M.

• Consolidated revenue estimate for the year is $55-$56M, including $0.6–0.75M in royalty revenue.

• Vascepa/Pasipa revenue growth for the full year now expected in the mid-teens percentage, revised from 18%-26%.

• Canadian Clozaril business projected to decline 4%-5% for the full year, with inventory effects expected to impact 2025 comparisons; U.S. Clozaril guidance unchanged at 2–4% decrease.

• 2026 expected to see growth in both top-line and Adjusted EBITDA, with bempedoic acid launch contributing to revenue.